Trial Profile
A prospective study comparing rivaroxaban to the low-molecular-weight heparin (LMWH) dalteparin, the current standard of care, for the treatment of blood clots in patients with active cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cancer; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms CALLISTO
- 02 Jun 2015 New trial record
- 28 May 2015 This study is a part of CALLISTO clinical research program. This program consists of seven clinical studies and two observational registries.